Pacific Edge Placement Increased to NZ$25.4 Million

13 MAY 2026

NOT FOR DISTRIBUTION OR RELEASE INTO THE UNITED STATES

PACIFIC EDGE PLACEMENT INCREASED TO NZ$25.4 MILLION
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge Limited (Pacific Edge
or the Company) (NZX/ASX: PEB) today announces it has successfully raised NZ$25.4 million
of new equity in a placement of new ordinary shares (Placement), after the Directors resolved
to increase the Placement and accept oversubscriptions following strong investor demand.
The Placement, which was well supported by existing institutional and other investors, was
completed on Tuesday, 12 May 2026. It was priced at NZ$0.17 per share, a 2.3% discount to
the closing share price on 8 May 2026, prior to the announcement of the company’s planned
equity issue.
As previously announced, Pacific Edge intends to conduct a retail offer to eligible existing
shareholders to raise up to NZ$6 million at the same offer price of NZ$0.17 per share (with the
ability to accept oversubscriptions at Pacific Edge’s discretion) (Retail Offer). Full details of
the Retail Offer will be set out in the Retail Offer Document, which will be released to the NZX
and ASX, and sent to eligible shareholders on Thursday, 14 May 2026.
The Placement and Retail Offer are aimed at ensuring Pacific Edge has additional resources
and capacity to support ongoing operations and growth, support the company to achieve
Medicare re-coverage, and continue evidence generation, product development and
innovation.
Chairman, Simon Flood said: “We are delighted with the investor support we have received.
The new capital will allow us to consolidate our market position in bladder cancer diagnostics.
It will support the Company and its operations to regain Medicare coverage and assist our
move towards the broader adoption of our tests by commercial payers in the US and further
afield. We are determined not to lose that momentum.”
Pacific Edge Chief Executive, Dr Peter Meintjes, said: “The robust evidence emerging from our
clinical evidence program is shifting clinical sentiment towards the broader adoption of our tests
with opportunities in the US and in the Asia Pacific Region. We are delighted with the strong
support we have received from investors in the Placement to continue to pursue our plans, and
we are looking forward to making the Retail Offer to eligible shareholders at the same offer
price.”
Pacific Edge is advised on the equity raise by Cameron Partners (investment banking
advisers), Harmos Horton Lusk (legal advisers) and The Project (investor relations and
communications advisers).
For further information on the detail and timetable of the equity raising please refer to the
announcement and presentation dated Friday, 8 May 2026 and released by NZX and ASX on
Monday, 11 May 2026.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

2
NOT FOR DISTRIBUTION OR RELEASE INTO THE UNITED STATES

For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263
OVERVIEW OF PACIFIC EDGE
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with microhematuria and those being monitored for
recurrent disease. The tests help improve the overall patient experience, while prioritizing time
and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
25 peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.